Didanosine: profile and news

Oscient Pharmaceuticals Reports Financial Results for Fourth ... 06 Mar 2006
Drug-drug interactions include probenicid, sucralfate, antacids containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine. ... - Genetic Engineering News,

Fringe wins for pharma, but cos seek stronger dose Feb 28, 2006
Budget. Some of these drugs are cisplatin, stavudine, danazol and didanosine. However, the industry sees these as minor concessions. ... - Economic Times,

Gilead Sciences Welcomes Guidance From Nice On Treatment Of ... Feb 22, 2006
...dipivoxil 60 mg administered concomitantly with saquinavir soft capsules resulted in a 20 % increase in adefovir AUC and a 29 % increase in didanosine AUC when ... - Medical News Today (press release),

Simplified treatment regimens show promise in HIV-infected ... Feb 6, 2006
They treated the patients with a once-daily regimen of three anti-HIV drugs comprising ddI (didanosine, Videx / Videx EC), FTC (emtricitabine, Emtriva) and ... - Aidsmap,

CROI: Low rates of resistance seen in Staccato trial of CD4-guided ... Feb 26, 2006
NRTIs). These were either d4T (stavudine, Zerit) and ddI (didanosine, VidexEC) or tenofovir (Viread) and 3TC (lamivudine, Epivir). ... - Aidsmap,

Barr Reports Second Quarter Fiscal 2006 GAAP Earnings of $0.88 Per ... Feb 7, 2006
...increase is primarily related to strong sales of the Company's Desmopressin product that was launched in July 2005 and sales of its Didanosine product that was ... - MSN Money

CROI: Capsaicin patch helps relieve neuropathy Feb 10, 2006
It is caused both by HIV and by certain HIV medications, such as ddI (didanosine, Videx / VidexEC), ddC (zalcitabine, Hivid) and d4T (stavudine, Zerit ... - Aidsmap,

CROI: Tenofovir and kidney toxicity - low rates seen, but some ... Feb 9, 2006
Abstract #778. Crane H Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir. ... - Aidsmap,

Barr reports strong quarterly earnings Feb 8, 2006
...was largely attributable to Barr's introductions of its versions of desmopressin, used to treat bed wetting and frequent urination, and didanosine, an HIV drug ... - The Journal News.com,

CROI: AZT, 3TC and FTC achieve good concentrations in the female ... Feb 17, 2006
The women were treated with antiretroviral regimens that included 3TC, AZT, abacavir (Ziagen), ddI (didanosine, Videx), d4T (stavudine, Zerit), efavirenz ... - Aidsmap,

Multi-component drug delivery system: An emerging trend Feb 8, 2006
3TC (Epivir), tenofovir (Viread), abacavir/lamivudine /zidovudine (Trizivir), lamivudine/zidovudine (Combivir), stavudine, d4T (Zerit), didanosine, ddI (Videx ... - Express Pharma Pulse,

CROI: Tenofovir and kidney toxicity - low rates seen, but some ... 09 Feb 2006
Abstract #778. Crane H Didanosine and lower baseline body weight are associated with declining renal function among patients receiving tenofovir. ... - Aidsmap,

Bristol-Myers Squibb and Gilead Announce Data Supporting ... Jan 9, 2006
Drug interactions have been observed when didanosine, atazanaviror lopinavir/ritonavir is co-administered with Viread and doseadjustments may be necessary. ... - Finanzen.net,

Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ... Jan 18, 2006
Drug interactions have been observed when didanosine, atazanavir, or lopinavir/ritonavir are co-administered with Viread, a component of Truvada, and dose ... - Genetic Engineering News,

Drug price reduction makes Aids manageable Jan 25, 2006
Since then, it has secured voluntary licenses from Bristol-Myers Squibb (for stavudine and didanosine), Boehringer Ingleheim (for nevirapine) and Merck Sharp & ... - iAfrica.com,

FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New ... Jan 20, 2006
Drug-drug interactions include probenicid, sucralfate, antacids containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine. ... - Genetic Engineering News,

Increase ribavirin dose for better HCV treatment response in ... Jan 18, 2006
...therapy. Exclusion criteria include psychiatric illness, alcohol abuse, ddI (didanosine, Videx / VidexEC) use, and cirrhosis. Around ... - Aidsmap,

Unaffordable AIDS Drug Prices... Again 11 Dec 2005
Didanosine EC, a drug used in many second-line regimens, costs about $400 in Cameroon (a median price in the survey), even though a WHO study recently found ... - Doctors Without Borders,

New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the ... Dec 9, 2005
Drug-drug interactions include probenicid, sucralfate, antacids containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine. ... - Genetic Engineering News,

AIDS Patients on Tenofovir Must Be Monitored For Renal Failure ... Nov 14, 2005
Three of these patients were taking at least two other drugs that interact with tenofovir (ritonavir, lopinavir, didanosine, atazanavir). ... - DG News

What’s your problem? Dec 7, 2005
The nucleoside drugs , particularly stavudine (d4T, Zerit) and didanosine (ddI, Videx), are the drugs most implicated in causing lipoatrophy. ... - NAPWA,

HIV Virus Emerging Drug Resistant In UK, Prompting Fear Of A ... Nov 18, 2005
The currently available drugs are Zidovudine, Stavudine, Lamivudine, Abacavir, Indinavir, Efavirenz, Nevirapine and Didanosine. ... - MedIndia,

The overuse of Tamiflu in treating avian flu Dec 2, 2005
Three or four antiretrovirals (ao zidovudine, didanosine, nefirapine, and indinavir) have been contributing modestly to the treatment of HIV-positive patients. ... - Jakarta Post,

Preliminary 24-Week Data Evaluating the Impact of Switching from ... Nov 17, 2005
Drug interactions have been observed when didanosine,atazanavir, or lopinavir/ritonavir are co-administered with Viread, acomponent of Truvada, and dose ... - Finanzen.net,

Switching from twice-daily Combivir to once-daily Truvada in ... Nov 23, 2005
Drug interactions have been observed when Didanosine, Atazanavir, or Lopinavir/Ritonavir are co-administered with Viread, a component of Truvada, and dose ... - Xagena.it,

Fat loss may be restored with dietary supplement Nov 14, 2005
...loss. People receiving ddI (didanosine) were specifically excluded from the Finnish study since ddI is a pyrimidine analogue. Neither ... - Aidsmap,

Once-daily boosted saquinavir has low blood levels when used with ... Nov 11, 2005
Once-daily regimen of saquinavir, ritonavir, didanosine and lamivudine in HIV-1 infected patients with standard tuberculosis therapy (TBQD study). ... - Aidsmap,

Simplicity is the Key to Survival in the HIV Market where Older ... Nov 15, 2005
The report includes an assessment of the impact of generic antiretrovirals and a case analysis of generic didanosine, FDA tentative approval of NNRTIs ... - PharmaLive.com (press release),

Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ... Oct 7, 2005
Drug-drug interactions include probenicid, sucralfate, antacids containing aluminum or magnesium, iron, multivitamins containing metal cations, and didanosine. ... - Genetic Engineering News,

Reverset Delay Of Phase III Sends Incyte Stock Reeling Sep 28, 2005
The previous Phase II study found that half of patients receiving 200 mg of Reverset with ddl (didanosine) experienced asymptomatic increases in serum lipase ... - BioWorld Online (subscription),

Efavirenz may linger for up to eight weeks after treatment stops Sep 27, 2005
...treatment for almost six months, and her viral load remained below 400 copies/ml 28 days after stopping a regimen of ddI (didanosine, Videx), hydroxyurea, 3TC ... - Aidsmap,

First HIV Drug, Glaxo's AZT, Gets Generic US Rivals (Update1) Sep 19, 2005
...last year won US approval to sell a generic version of Bristol-Myers Squibb Co.'s Videx HIV drug, or didanosine, according to the FDA's Web site. ... - Bloomberg

Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
Overview of Results "New generic product launches including Didanosine and two generic oral contraceptives, and record proprietary sales of $279 million driven ... - PR Newswire (press release),

Barr Reports GAAP Earnings of $2.03 Per Share for Fiscal 2005 and ... 08 Sep 2005
..."New generic product launches including Didanosine and two generic oral contraceptives, and record proprietary sales of $279 million driven by sales of our ... - Finanzen.net,

Gilead Reduces Prices for Viread and Truvada in the Developing ... Aug 29, 2005
Drug interactions have been observed when didanosine, atazanavir or lopinavir/ritonavir is co-administered with Viread and dose adjustments may be necessary. ... - PharmaLive.com (press release),

In this thing together Sep 1, 2005
The first line drugs comprise Zidovudine, Lamivudine, Neveripine and Efavirenz; while the second line drugs include Didanosine, Stavudine, and Nelfinavir. ... - Mmegi,

US men's study finds cumulative NRTI use, but not PIs or NNRTIs ... Aug 24, 2005
But although 26% were receiving AZT (zidovudine, Retrovir) and 17% were receiving ddI (didanosine, Videx/VidexEC), neither were found to be associated with ... - Aidsmap,

Risk of peripheral neuropathy five times higher for common genetic ... Aug 25, 2005
...places these individuals at five-fold higher risk of developing peripheral neuropathy after exposure to d4T/ddI (stavudine and didanosine) according to an ... - Aidsmap,

Anti-HIV drugs linked with nerve damage Aug 26, 2005
The condition is known to be associated with several anti-HIV drugs called dideoxynucleosides: didanosine, zalcitabine and stavudine. ... - Macleans,

Acute Bacterial Sinusitis - Levaquin® (levofloxacin) FDA Approved ... Aug 15, 2005
...magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc, or Videx** (didanosine) chewable/buffered ... - Medical News Today (press release),

Timeline: AIDS in America Aug 13, 2005
...activist, die. * The FDA approves ddI (didanosine, Videx by Bristol-Myers Squibb), a nucleoside reverse transcriptase inhibitor. The ... - Knoxville News Sentinel (subscription),

Phase IIb Study Shows Reverset(TM) Has Potent Antiviral Activity ... Jul 25, 2005
...to greater than 5 times the upper limit of the normal range (Grade 4) were seen in 50% of patients receiving 200 mg Reverset with ddI (didanosine), and we have ... - Business Wire (press release)

Incyte shares fall on study results Jul 25, 2005
Incyte also said Monday that about half of patients taking the strongest dose of Reverset together with an HIV therapy called didanosine experienced higher-than ... - BusinessWeek

Epidemiology Study Reports New Information on Hypersensitivity ... Jul 26, 2005
1 (HXB2) containing multiple reverse transcriptase mutations conferring ZIAGEN resistance exhibited cross- resistance to lamivudine, didanosine and zalcitabine ... - Yahoo News (press release)

Incyte's HIV Drug Reverset in Phase II Trial Shows Potential in ... Jul 27, 2005
Two study participants who were taking the 100-milligram dose with the FDA-approved antiretrovirals didanosine and tenofovir experienced symptoms of ... - Kaiser network.org

Gilead Sciences and Royalty Pharma Announce $525 Million Agreement ... Jul 18, 2005
Drug interactions have been observed when didanosine, atazanavir or lopinavir/ritonavir is co-administered with Viread and dose adjustments may be necessary. ... - Business Wire (press release)

IAS: New NRTI D-d4FC active in treatment-experienced patients Jul 28, 2005
The study also showed that the drug should not be used with ddI (didanosine, Videx / VidexEC), due to an elevated risk of side-effects. ... - Aidsmap

MSD grants Aspen generic licence Jul 19, 2005
Efavirenz is a welcome addition to our existing ARV basket which is presently comprised of Aspen Stavudine, Aspen Didanosine, Aspen Nevirapine, Aspen ... - Sunday Times

More to come Jul 19, 2005
Saad explained efavirenz is the last drug needed to complete Aspen’s arsenal of ARVs, which includes Aspen Stavudine, Aspen Didanosine, Aspen Nevirapine ... - Moneyweb

Other information

Indication
For treatment of Human immunovirus (HIV) infections

Pharmacology
Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Didanosine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

Mechanism Of Action
Didanosine (ddI) is metabolized intracellularly by a series of cellular enzymes to its active moiety, 2,3–dideoxyadenosine-5-triphosphate (ddA-TP), which inhibits HIV DNA polymerase (reverse transcriptase). Didanosine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.

Drug Category
Anti-HIV Agents; Antimetabolites; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; ATC:J05AF02

Brand Names/Synonyms
2'3'-DIDEOXYINOSINE; 2DI; CCRIS 805; DDI; DIDEOXYINOSINE; Ddi; Ddi, Didanosine; Didanosine; Didanosine [Usan:Ban:Inn]; Dideoxyinosine; Videx; Videx Ec; [Inn-Latin]; [Inn-Spanish]

Dosage Forms
CAPSULE (ENTERIC-COATED); POWDER FOR SOLUTION; TABLET

Absorption
Rapidly absorbed (bioavailability = 30-40%) with peak plasma concentrations appearing within 0.5 and 1.5 hrs.

Interactions
Coadministration of VIDEX with drugs that are known to cause pancreatitis may increase the risk of this toxicity (see WARNINGS) and should be done with extreme caution, only if other alternatives are not available, and only if clearly indicated. Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including stavudine, and these patients may be at increased risk of neuropathy during VIDEX therapy (see ADVERSE REACTIONS). Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min). The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known. Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components. Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX. Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12). A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12). Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum. In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX. The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently. In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed. Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum. The optimal dosing interval for coadministration with VIDEX should be determined by consulting the appropriate quinolone package insert. Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX. To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX. The pharmacokinetics of nelfinavir are not altered to a clinically significant degree when it is administered with a light meal 1 hour after VIDEX.

Chemical IUPAC Name
9-[5-(hydroxymethyl)tetrahydrofuran-2-yl]-3,9-dihydropurin-6-one

Chemical Formula
C10H12N4O3

Half Life
1.5 +/- 0.4 hours

Drug Type
Approved Drug

# Accession No
APRD00240

CAS Registry Number
69655-05-6